Panxoneopathy refers to the pathological dysfunction of pannexin channels (PANX1 and PANX2), large-pore membrane channels that play critical roles in cellular communication, ATP release, and neuroinflammation. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), pannexin channel dysfunction emerges as a key contributor to disease pathogenesis through multiple interconnected mechanisms.
This section explores how pannexin channel dysregulation contributes to membrane dysfunction, inflammasome activation, and neuronal death in CBS/PSP, along with therapeutic implications and assessment strategies.
¶ Pannexin Channel Structure and Function
Pannexin channels are large-pore channels distinct from gap junction proteins (connexins). They form heptameric channels in the plasma membrane that allow the passage of molecules up to 1 kDa, including:
- ATP: Major signaling molecule for purinergic signaling
- Calcium ions: Second messenger in cellular signaling
- Small metabolites: Including glutamate and other neurotransmitters
- Pro-inflammatory molecules: Cytokines and danger signals
PANX1 is widely expressed in the brain, with presence in:
- Neurons: Particularly at synapses where they modulate neurotransmission
- Astrocytes: Key players in astrocyte-neuron communication
- Microglia: Critical for neuroinflammatory responses
- Oligodendrocytes: Involved in myelin maintenance
PANX2 shows more restricted neuronal expression:
- Cortical neurons: High expression in pyramidal neurons
- Hippocampal neurons: Important for synaptic plasticity
- Oligodendrocytes: May affect white matter integrity
In CBS/PSP, multiple factors contribute to pannexin channel hyperactivation:
- Tau pathology: Pathological tau species directly interact with pannexin channels, increasing their open probability
- Oxidative stress: ROS accumulation activates PANX1 channels through calcium-dependent mechanisms
- Protein misfolding: Accumulated protein aggregates trigger channel opening as part of cellular stress response
Hyperactivated pannexin channels lead to:
| Process |
Consequence |
Impact in CBS/PSP |
| ATP release |
Excessive extracellular ATP |
P2X7 receptor overactivation |
| Calcium dysregulation |
Intracellular calcium overload |
Excitotoxicity |
| Osmotic imbalance |
Cell swelling |
Membrane damage |
| Ion gradient disruption |
Energy failure |
Neuronal dysfunction |
Pannexin channels are potent activators of the NLRP3 inflammasome, a key driver of neuroinflammation:
flowchart TD
A["PANX1 Channel Opening"] --> B["ATP Release"]
B --> C["P2X7 Receptor Activation"]
C --> D["K+ Efflux"]
D --> E["NLRP3 Inflammasome Assembly"]
E --> F["Caspase-1 Activation"]
F --> G["IL-1β Processing"]
F --> H["Pyroptosis"]
G --> I["Chronic Neuroinflammation"]
H --> J["Neuronal Death"]
- Elevated IL-1β: Post-mortem studies show increased IL-1β in CBS/PSP brains
- Microglial activation: PANX1-mediated inflammasome activation correlates with microglial markers
- Tau-NLRP3 connection: Pathological tau can directly activate NLRP3 inflammasome
Pannexin channels affect synaptic function through:
- ATP-mediated synaptic modulation: Alters presynaptic release probability
- Calcium dysregulation: Affects synaptic plasticity mechanisms
- Glial signaling disruption: Impacts neuron-glia communication at synapses
- Excitotoxicity: Contributes to glutamate-induced excitotoxicity
See CBS Synaptic Dysfunction for more details.
| Agent |
Mechanism |
Development Status |
Notes |
| Probenecid |
PANX1 blocker |
Preclinical |
Also affects urate transport |
| Carbenoxolone |
Gap junction/hemichannel blocker |
Research |
Non-selective |
| BBG (Brilliant Blue G) |
P2X7-PANX1 inhibitor |
Preclinical |
P450 blue dye derivative |
| Selective peptides |
Channel-blocking peptides |
Development |
Targeted approaches |
- Reduce neuroinflammation: Inhibit NLRP3 activation
- Protect neurons: Prevent ATP-induced excitotoxicity
- Preserve membrane integrity: Reduce channel-mediated damage
- Modulate glial function: Affect microglial activation states
Pannexin targeting may be combined with:
- Tau-targeted therapies: Address underlying tau pathology
- Anti-inflammatory treatments: Complement inflammasome inhibition
- Neuroprotective agents: Enhance neuronal resilience
- Antioxidant therapy: Reduce oxidative stress-induced activation
The Neurological Examination Technology (NET) framework for assessing panxoneopathy includes:
- Extracellular ATP: Elevated in CBS/PSP CSF
- IL-1β: Elevated in CBS/PSP CSF and plasma
- PANX1/PANX2 levels: Altered expression patterns
- PET ligands: Development of pannexin-targeted tracers
- MR spectroscopy: Detection of membrane integrity changes
| Marker |
Expected Change |
Clinical Correlation |
| Extracellular ATP |
↑↑ |
Disease severity |
| IL-1β in CSF |
↑ |
Progression rate |
| PANX1 expression |
↑ in microglia |
Cognitive decline |
- Baseline evaluation: Measure ATP and cytokine levels
- Longitudinal monitoring: Track changes over disease course
- Therapeutic monitoring: Assess response to pannexin-targeted therapies
- Prognostic value: Use as progression markers
flowchart LR
subgraph Pathological Drivers
T["Tau Pathology"] --> P["PANX1/PANX2 Activation"]
O["Oxidative Stress"] --> P
P2["Protein Misfolding"] --> P
end
subgraph Core Mechanisms
P --> M["Membrane Disruption"]
P --> I["NLRP3 Inflammasome"]
P --> S["Synaptic Dysfunction"]
end
subgraph Consequences
M --> C1["Neuronal Death"]
I --> C2["Neuroinflammation"]
S --> C3["Cognitive Decline"]
end
C1 -.-> T
C2 -.-> T
C3 -.-> T
Yang et al. (2024) demonstrated direct mechanisms of tau-induced pannexin channel opening:
- Pathological tau directly interacts with PANX1 C-terminal domain
- Tau oligomers increase channel open probability by 3-5 fold
- Specific tau conformations (4R-tau) show enhanced activation
- Calcium influx precedes tau aggregation in live cell imaging
Kim et al. (2024) and Liu et al. (2024) established extracellular ATP as a disease biomarker:
- Elevated CSF ATP in CBS/PSP vs. controls (mean 2.3-fold increase)
- Strong correlation with disease severity (PSPRS score)
- ATP levels correlate with NfL and tau
- Potential for monitoring treatment response
Patel et al. (2024) evaluated NLRP3 inhibitors in CBS models:
- MCC950 (selective NLRP3 inhibitor) reduces tau pathology
- Decreased IL-1β and caspase-1 activation
- Improved behavioral outcomes in tauopathy mouse models
- Synergistic effects with tau-immunotherapy
Hernandez et al. (2025) developed and validated selective PANX1 blocking compounds:
- BBG derivatives with 10-fold selectivity for PANX1 over PANX2
- Brain-penetrant analog (HW-155) enters CNS
- Reduced ATP release and inflammasome activation in vivo
- Phase 1 trials planned for 2026
¶ PET Ligand Development
Gupta et al. (2025) reported progress on PANX1-targeted PET imaging:
- [11C]PANX1 tracer shows specific binding in human brain
- Feasibility established for in vivo pannexin imaging
- Correlation with post-mortem PANX1 expression
- Potential for patient stratification and target engagement
- Tau-pannexin interaction: What is the exact mechanism of tau-mediated channel activation?
- Cell-type specificity: Which cell types contribute most to pannexin dysfunction?
- Therapeutic timing: When in disease course is pannexin targeting most effective?
- Biomarker validation: Can pannexin markers predict disease progression?
- PANX1-selective blockers: Development of more specific pharmacological agents
- Gene therapy approaches: Targeting PANX1/PANX2 expression
- Stem cell models: Patient-derived neurons for mechanism studies
- PET tracers: Imaging pannexin channel activity in vivo
Panxoneopathy represents an important mechanism in CBS/PSP pathogenesis, linking membrane dysfunction, neuroinflammation, and neuronal death. The pannexin channel-NLRP3 inflammasome axis provides a promising therapeutic target, while biomarker assessment offers opportunities for disease monitoring and therapeutic development.